Oprozomib was granted orphan drug status for the treatment of Waldenstrom's macroglobulinaemia and multiple myeloma in 2014.
2.
As of February 2016, acalabrutinib had received orphan designation in the United States for CLL only, and was similarly designated as an orphan medicinal product by the European Medicines Agency ( EMA ) Committee for Orphan Medicinal Products ( COMP ) for treatment of three indications-chronic lymphocytic leukemia ( CLL ) / small lymphocytic lymphoma ( SLL ), mantle cell lymphoma ( MCL ), and lymphoplasmacytic lymphoma ( Waldenstr�m's macroglobulinaemia, MG ).
मोबाइल